FeynMed Solutions

FeynMed Solutions is an Edmonton-based biotechnology company specializing in the development of next-generation nanotherapeutics using precisely engineered nanocrystalline silver. The company utilizes a proprietary physical vapour deposition process to create nanomaterials with controlled structural properties, such as grain size and atomic organization, designed to provide potent antimicrobial and anti-inflammatory effects. This versatile platform technology aims to deliver site-specific therapies through tunable formulations, addressing a broad range of medical challenges including acute and chronic wounds, abdominal adhesions, pulmonary infections, urinary tract infections, and ocular diseases. The company operates a purpose-built cGMP pilot facility in Edmonton to support scalable manufacturing and product development.

By targeting both immediate market opportunities like advanced wound dressings and high-need areas in surgery and internal medicine, FeynMed Solutions seeks to improve patient outcomes while reducing the reliance on traditional antibiotic and silver-based treatments. The company is actively navigating regulatory pathways, including FDA 510(k) submissions, and has secured non-dilutive grant funding from organizations like Alberta Innovates and the National Research Council of Canada. Led by a multidisciplinary team of scientists, clinicians, and industry experts—including co-founder Dr. Robert Burrell, a recognized leader in infection treatment—FeynMed focuses on transitioning innovative laboratory science into clinical-grade commercial products for global healthcare markets.